青年与中老年脑卒中危险因素及预后的对比分析
|
摘要
目的:比较青年脑卒中与中老年脑卒中危险因素与预后的不同,为临床诊治以及预防提供一定的依据。
方法:在卒中资料库中抽取资料完整的≤45岁以及>45岁脑卒中患者各150例,对已知的危险因素进行比较分析,并对患者卒中后6个月,1年临床随访,以了解患者的服药情况,有无复发以及目前的生活自理能力(BI)评分。
结果:青年缺血性脑卒中前三位的危险因素是高血压病、吸烟、酗酒,其次为糖尿病、高脂血症、不明原因以及动脉狭窄,老年组前三位为高血压病、高脂血症、吸烟、其次为酗酒、糖尿病、动脉狭窄以及心脏病,两组比较,青年组吸烟、酗酒比例38.46%、37.61%高于老年组25.68%、23.85%,p分别为0.04和0.025;高脂血症、糖尿病的比例10.26%、11.11%低于老年组28.84%、22.01%,p分别为0.001和0.027。出血性脑血管病的危险因素中,青年组酗酒的比例高达51.51%高于老年组29.27%,p=0.028。随访卒中后6个月及1年青年缺血性脑卒中恢复良好的比例高于中老年组,残疾比例、死亡比例及复发比例低于中老年组,p分别为0.049和0.022。出血性脑卒中6个月及1年预后比较,p分别为0.578和0.411,差异无统计学意义。
结论:①青年脑卒中的危险因与中老年脑卒中相比同样复杂而多样。②青年脑卒中预后好于老年组③倡导全民健康的四大基石:合理饮食,适当运动,戒烟限酒,身心平衡
Objective: Compare the difference of risk factors and prognosis beween young and old patients with stroke and provide a basis for clinical treatment and prevention.
Methods: One hunderd and fifty stroke patients under 45 years and over 45 years which have complete information was respectively extracted in the stroke database. Known risk factors were comparative analyzed and the patients after stroke at the sixth months and the first year were clinical followed-up.
Results:The first three risk factors of young ischemic stroke are hypertension disease,smoking and alcohol abuse,followed by diabetes, hyperlipemia, unknown cause and arterial stenosis. The first three risk factors of elderly ischemic stroke are hypertension disease, hyperlipidemia and smoking, followed by alcoholism, diabetes, arterial stenosis and heart disease.The ratio of smoking in young group(38.46%) was remarkably higher than in old group(25.68% )(P=0.04).The ratio of alcohol abuse in young group(37.61%) was remarkably higher than in old group(23.85% )(P=0.025). The ratio of hyperlipidemia in young group(10.26%) was lower than in old group(28.84% )(P=0.001). The ratio of diabetes in young group(11.11%) was lower than in old group(22.01% )(P=0.027).On the other hand,alcohol was considered as a risk factor for hemorrhagic cerebrovascular diseaseas .The ratio of alcohol in young group as high as 51.51% higher than the old group 29.27%, p=0.028. Through following-up sixth months and first year after ischemic stroke ,a recovery of the young group was higher than the middle-aged group(p=0.049), whereas the proportion of disability, death and recurrence ratio of the young group was lower than the middle-aged group(p=0.022).On the hand , through following-up sixth months and first year after hemorrhagic stroke ,a recovery and the proportion of disability, death,recurrence ratio were no significant difference between the young group and the middle-aged group(p=0.578,P=0.411).
Conclusion:①The risk factors of young stroke is complex and multiplicity, compares with the middle and old aged apoplexy.②The prognosis of ischemic stroke in young group was better than the elderly group.③Our proposition is reasonable diet, suitable activity, no-smoking and limited the liquor, The body and mind is balanced.
方法:在卒中资料库中抽取资料完整的≤45岁以及>45岁脑卒中患者各150例,对已知的危险因素进行比较分析,并对患者卒中后6个月,1年临床随访,以了解患者的服药情况,有无复发以及目前的生活自理能力(BI)评分。
结果:青年缺血性脑卒中前三位的危险因素是高血压病、吸烟、酗酒,其次为糖尿病、高脂血症、不明原因以及动脉狭窄,老年组前三位为高血压病、高脂血症、吸烟、其次为酗酒、糖尿病、动脉狭窄以及心脏病,两组比较,青年组吸烟、酗酒比例38.46%、37.61%高于老年组25.68%、23.85%,p分别为0.04和0.025;高脂血症、糖尿病的比例10.26%、11.11%低于老年组28.84%、22.01%,p分别为0.001和0.027。出血性脑血管病的危险因素中,青年组酗酒的比例高达51.51%高于老年组29.27%,p=0.028。随访卒中后6个月及1年青年缺血性脑卒中恢复良好的比例高于中老年组,残疾比例、死亡比例及复发比例低于中老年组,p分别为0.049和0.022。出血性脑卒中6个月及1年预后比较,p分别为0.578和0.411,差异无统计学意义。
结论:①青年脑卒中的危险因与中老年脑卒中相比同样复杂而多样。②青年脑卒中预后好于老年组③倡导全民健康的四大基石:合理饮食,适当运动,戒烟限酒,身心平衡
Objective: Compare the difference of risk factors and prognosis beween young and old patients with stroke and provide a basis for clinical treatment and prevention.
Methods: One hunderd and fifty stroke patients under 45 years and over 45 years which have complete information was respectively extracted in the stroke database. Known risk factors were comparative analyzed and the patients after stroke at the sixth months and the first year were clinical followed-up.
Results:The first three risk factors of young ischemic stroke are hypertension disease,smoking and alcohol abuse,followed by diabetes, hyperlipemia, unknown cause and arterial stenosis. The first three risk factors of elderly ischemic stroke are hypertension disease, hyperlipidemia and smoking, followed by alcoholism, diabetes, arterial stenosis and heart disease.The ratio of smoking in young group(38.46%) was remarkably higher than in old group(25.68% )(P=0.04).The ratio of alcohol abuse in young group(37.61%) was remarkably higher than in old group(23.85% )(P=0.025). The ratio of hyperlipidemia in young group(10.26%) was lower than in old group(28.84% )(P=0.001). The ratio of diabetes in young group(11.11%) was lower than in old group(22.01% )(P=0.027).On the other hand,alcohol was considered as a risk factor for hemorrhagic cerebrovascular diseaseas .The ratio of alcohol in young group as high as 51.51% higher than the old group 29.27%, p=0.028. Through following-up sixth months and first year after ischemic stroke ,a recovery of the young group was higher than the middle-aged group(p=0.049), whereas the proportion of disability, death and recurrence ratio of the young group was lower than the middle-aged group(p=0.022).On the hand , through following-up sixth months and first year after hemorrhagic stroke ,a recovery and the proportion of disability, death,recurrence ratio were no significant difference between the young group and the middle-aged group(p=0.578,P=0.411).
Conclusion:①The risk factors of young stroke is complex and multiplicity, compares with the middle and old aged apoplexy.②The prognosis of ischemic stroke in young group was better than the elderly group.③Our proposition is reasonable diet, suitable activity, no-smoking and limited the liquor, The body and mind is balanced.
引文
[1]毕齐,张茁,张薇薇,等.2359例青年脑卒中危险因素的研究[J].中华流行病学杂志,2003,24(2):106-108
[2]王新德.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29:379-381
[3] Truelsen T ,Heuschmann P ,Bonita R ,et al . Standard method for developing stroke registers in low-income and middle-in- come countries :experiences f rom a feasibility study of a step-wise approach to stroke surveillance (STEPS Stroke) [J] . Lancet Neurol, 2007 ,6 :134-139
[4] Hirano T. Latest clinical trend of stroke epidemiology shown by Stroke Data Bank[J]. Nippon Rinsho ,2006 ,28 :6447-6450
[5] Liu M ,Wu B ,Wang WZ ,et al . Stroke in China :Epidemiology prevention and management strategies[J]. Lancet Neurol,2007 ,6 :456-464
[6]安中平,张东威,巫嘉陵.2103例脑卒中登记患者发病危险因素分析[J].中华老年心脑血管病杂志,2008,(10) 4 :283-285
[7] Seenan P ,Long M ,Langhorne P. Stroke units in their natural habitat . Systematic review of observational studies[J]. Stroke,2007 ,38 :1886-1892
[8] Hozawa A ,Murakami Y,Okamura T. Relation of adult height with stroke mortality in Japan : NIPPON DATA80[J]. Stroke ,2007,38:22-26
[9] Bang OY,Park HY,Lee PH. Improved outcome after atherosclerotic stroke in male smoker . J Neurol Sci[J] ,2007 ,260 : 432
[10] Poger X,John J,M cneil,et al. Risk factors for stroke due to cerebral infarction in young adult[J].Stroke,1997,28:1913
[11]李丽娟,李巧薇,谭少华.青年缺血性卒中的危险因素、TOAST病因分型及预后分析[J].广东医学,2008,29(6):1012-1013
[12]张润兰.青年卒中临床特点和危险因素分析[J].中国误诊学杂志,2009, 9(24) :5822-5823
[13]于克文,李玉花,赵婷婷.青年、中青年脑卒中的性别差异及危险因素分析[J].中国临床神经科学,2006,14( 1):91-92
[14]丁建平宿英英.青年脑梗死病因及危险因素分析[J].中国脑血管病杂志, 2008, 5(5):202-206
[15]刘竞丽李劲频.青年缺血性脑卒中TOAST分型的临床意义[J].卒中与神经疾病,2007,14(6):341-343
[16]沙瑞娟,张宙,余天浩,等.青年人脑梗死与脑出血患者的病因、危险因素及预后: 293例对比分析[J].中国临床康复,2004,31(8):6836-6839 [17 ]王德生,徐心,李树祥,等.中青年脑梗塞患者的临床与病理[J].中华神经科杂志, 1998,31(2):98-101
[18 ] Lee TH, HsuWC, Chen CJ, et al. Etiologic study of young ischemic stroke in Taiwan[J]. Stroke,2002,33(8):1950-1955
[19] Devic B,Bradford BurkeW, (著) ,孙继洲,孙翠梅(译) .卒中遗传学和炎性机制[J].国外医学脑血管疾病分册, 2004,12(2):155-159
[20] Hillbom M, Haapaiemi H, Juvela S, et al. Recant alcohol consumption, cigarette smoking, and cerebral infarction in young adults[ J ].Stroke, 1995, 26 (1) : 40-45
[21] Cordon DL, Bendixen BH, Adams HP J r, et al. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST Investigators[ J ]. Neurology, 1993, 43 (5) : 1021-1027
[22]申小茜.青年脑梗死48例危险因素分析[ J ].中国基层医药,2004, 11 (6) : 747
[23]沙瑞娟,张宙,余天浩,等.青年人脑梗死与脑出血患者的病因、危险因素及预后: 293例对比分析[J].中国临床康复,2004,31(8):6836-6839
[24]陈善红,朱桂香,迟兆富,等.青年脑出血137例临床分析[J].中华神经医学杂志, 2005, 4 (3) : 259-261
[25] Nightingale AL , Farmer RD. Ischemic stroke in young women,a nested case-contro l study using the UK general practice research database[J ]. Stroke, 2004, 35 (7) : 1574-1578
[26]凌峰.脑血管病理论与实践.北京:人民卫生出版社,2007,31
[27]杨永宗.动脉粥样硬化性心血管病基础与临床.北京:科学出版社(第二版),2009,14
[28]杜敢琴,黄丽娜,高奇志,等.脑卒中预后的影响因素[J].中华神经医学杂志,2005,4(1):57-59
[29]徐恩,邓兵梅,梁睿,等.脑梗死患者近期预后影响因素分析[J].中国慢性病预防与控制,2004,12(2):61-63
[30] Ginberg MD,Busto R.Combating HY perthermia in acute stroke:A singnifacant clincal concern[J].Stroke,1998,29:529-534
[31] Kammergaard LP,Jorgense HS,Rungdy JA,et al.Admission body temperature predicts long-term mortality after acute stroke[J].Stroke,2002,33(7):1759-1762
[32]傅晓华,孙佳,李鸣培.体温控制治疗影响脑卒中患者的近期功能预后.中国临床康复,2005,9(25):4-5
[33]孙现广,卢奕南.急性脑卒中后就医时间与预后的关系[J].中风与神经疾病杂志,2001,8(2):100-107
[34] Msdonna P,de Stcfano V,Coppola A,et al.Hyperhomocyste inemia and other inherited prothrombotic condition in young adult with a history of ischemic stroke.Stroke, 2002, 33:51-56
[34] Eriksson J G,Forsen T,Tuomichto J,et al.Early growth,adult income,and risk of strokestroke.Stroke,2000,31:869-874
[35]朱平辉,欧阳秀革.刘春艳动态血压参数与原发性高血压患者靶器官损害的关系中国心血管病研究杂志, 2006 ,8:13
[36]吴泽兵,张颖,谢军.血压变异性与老年高血压患者腔隙性脑梗死的关系.中国临床保健杂志, 2010,3:13
[37] Najarian R,Sullivan L,Kannela W,et al.metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke.Arch Intern Med,2006,166:106-111
[1]凌锋,脑血管病理论与实践.北京:人民卫生出版社,2007,220
[2] Eham S,Ueda M ,Naruko T,et al. Elevated levels of oxidized low density lipoprotein show a positiverelationship with the severity of acute coronary syndromes [J]. Circulation,2001,103:1955-1960
[3]陈碧珊,苏丽华.他汀类药物的研究进展[J].中国药房,2005,16(7):545-546.
[4]李虹伟,彭晖.他汀类药物非调脂作用的研究进展[J].临床药物治疗杂志,2008,6(2):49-51
[5] Hofnagel O,Luechtenborg B,Eschert H,et al.Pravastatin Inhibits Expression of Lectin-like Oxidized Low-Density Lipoprotein Receptor (LOX-1) in Watanabe Heritable Hyperlipidemic hRabbits: A New Pleiotropic Effect of Statins.Arterioscler Thromb Vasc Biol,2006,26:604-610
[6] John S,Schneider M P,Delle s C,et al. Lipid-independent effect s of statin s on endothelial function and bioavailabi1ity of nitric oxide in hypercholesterolemic patients[J].Am Heart J,2005,149:473.
[7]孔德莲,沈霞.他汀类药物的非降脂作用[J].中国临床康复,2006,40(10):117-119.
[8]Premar-Oblak J,Sobestjen M,Sabovie M.Statin treatment improves cerebral more than systemic endothelial dysfunction in patien with arterial hypertension[J].Am J Hypertens,2008,21(6):674-676
[9]徐婕,龚建祖.辛伐他汀对高血压合并动脉粥样硬化患者内皮功能的影响.心脑血管病防,2009,(9)1:17-19
[10] Ahmet Yildiz,Akif Cakar,Murat Baskurt,et a1.The efects of atorvastatin therapy on endothelial function in patients with coronary artery disease[J].Cardiovascular Ultrasound,2007,30(5):51
[11] Ortego M,Bustes C,Hemandez-Presa MA,et a1.Atorvas-tatin reduces NF-kappaB activation and ehemokine expression in vascu1 ar smooth muscle cells and mononuclear cells[J].Athero-sclerosis,1999,47:253
[12] Schonbeck U,Gerdes N,Varo N,et a1.Oxidized low--density lipoprotein augments and 3-hydroxy 3methylglutaryl coenzyme A reductase inhibitors IimitCD40 and CD40L expression in human vascularcells[J].Circulation,2002,106:2888-2893
[13] Tunon J,Marti—n-Ventura J L,Blanco-Colio LM,et a1.Mechanisms of action of statins in stroke[J].Expert Opin.Ther Targets,2007,1l:273-278
[14] Notarbartolo A,Davi G,Averna M,et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in Type Iia hypercholesterolemia[J].Arterioscler Thromb Vasc Bio,1995,15:247-251
[15] Bourcier T.Libby HMGCoA reductase inhibitors reduce plasminogen activatorinhibitor-1 expression by human vascular smooth muscle and endothelia1 cells[J] .Arterioscler Thromb Vasc Biol,2000,20:556.562
[16] Knapp A C,Huang J,Starling G,et al. Inhibitors of HMGCOA reductase sensitize human smooth muscle cells to Fasligand and cytokineinduced cell death[J].Atherosclerosis,2000,152:217-227
[17] Wong B,Lumma WC,Smith AM,et al..Statins suppress THP ledl migration and secretion of matrix metalloproteinase 9 by inhibiting gerany1geranylation [J].J LeukocBiol,2001,69:959-962
[18] Blanco-Colio LM,Martin-Ventura儿,Gomez-Guerrero C,et a1.Adiponectin plasma evels are increased by atorvastatin treatment in subjects,at high cardiovascular risk. Eur J Pharmacol,2008,10:113-116
[19]董红梅,黄岚,宋耀明等.急性冠脉综合征患者血浆氧化型低密度脂蛋白、高敏C一反应蛋白与血管内皮损伤的关系[J].中国动脉硬化杂志,2006,14(3):227-229
[20] Cortellaro M,Cofrancesco E,Arbustini E,et al. Atorvastatin and thrombogenicity of the carotid Atherosclerotic plaque:the ATROCAP study.Thromb heamost,2002,88:41-47
[21] Taylor AJ,Kent SM,Flaherty PJ,et al.ARBITER:Arterial Biology for the Investigation of Treatment Effects of Reducing Cholesterol:a randomized trial comparing the effect of atorvastatin And pravastatin on carotid intima medial thickness[J].Cieculation,2002,106:2055-2060
[22] Nisscn S.Design and methedology 0f a study to evaluatethe efect of rosuvastatin on intravascular ultrasound—derived coronary atheroma burden (ASTEROID)[J].Atheroscler Suppl,2006,84(1):4-27
[23]Amarenco P,Labreuche J,Lavallee P, et al.Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J].Stroke,2004,35:2902-2909
[24] Colhoun HM , Betteridge DJ, Durrington PN, et al . P rimary prevention of cardiovascular diseae with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabete Study(CARDS): multicentre randomized place-controlled[J] .Lancet,2004,364:685-696
[25]李桂平彭娜李绪娴等.阿托伐他汀对2型糖尿病患者血管内皮功能及颈动脉粥样硬化的影响.实用医学杂志,2009,4:631-633
[26] Sacco RL,Adams R,Albers G,et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke:CO-sponsored by the COHnei1 on Cardiovascu1ar Radiology and Intervention:the American Academyof Neurology affirms the value of this guideline[J].Circulation,2006 ;113:409-449
[27] Amarenco P,Bogouss1aVsky J,Callahan A 3rd,et a1.High-dose atorvastatin after stroke or transient ischemic attack[J].N Engl J Med,2006,355:549-559
[28] Ovbiagele B,Saver JL.Itensive statin therapy after stroke or transient ischemic attack :a SPARCL success[J].Stroke,2007,38:1110-1112
[29] Antithrombotic Trialists’Collaboration.Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324:71- 86
[30] Rashid P,Lenoardi-Bee J,Bath P.Blood pressure reduction and secondary prevention of stroke and other vascular events:a systematic review[J].Stroke,2003.34:2741-2748
[31] National Cholesterol Education Program(NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood ChoLesterol in Adults Treatment PanelⅢ.Third Report of the National Cholosterol Education Program(NCEP)Expert Panel on Detection,Evaluation.and Treatment of High Blood Cholesterol in Adults Tteatment Panel m)final report[J]. Circulation,2002,106:3143-3421
[32] Newman CB,Palmer G,Silbershatz,et a1.Safety of atorvastatin derived from analysis of 44 completed trial s in 9416 patients[J].Am J Cardiol,2003,92:670-676
[33] Davidsonn MH,Toth PP.Combination therapy in the management of cornplex dyslipidemias[J].Gurr opin Lipidol,2004,15(4):423-431
[34] de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trial[J].JAMA,2004, 292:1307-1316.
[35] O’Regan C,Wu P,Arora P,et a1.Statin therapy in stroke prevention:a meta—analysis involving l2l,000 patients[J].Am J Med 2008,121:24-33.
[36] Alsheikh-Ali AA,M addukuri PV,Han H,et a1.Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes,Rhabdomyolysis,and Cancer[J].J Am Coil Cardiol,2007,50:409-418
[37]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35:390-427.
[38]张伟杰,唐伟方.他汀类药物的药动学及与其他药物的相互作用[J].药学进展,2009,33(3)119-123
[39] Sever PS,D ahlof B,Poulter NR,et a1.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than-average cholesterol concertrations:a multicentre randomized controlled trial[J].Lancet,2003,361:1149-1158.
[40] Schwartz G G, Olsson A G,Ezekowitz M D, et a1.Efects of atorvas tain on early recurrent ischemic events in acute coronary syndormes:the MIRACLE study.A randomizedcontrolled trial[J].JAMA,2001,285(1711):1718-1725.
[41] Adams RJ,Albers G,Alberts MJ,et a1.Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack[J]. Stroke,2008,39:1647-1652.
[42]他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组.他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识(更新版).中华内科杂志,2008,47(10):873-875
[43]中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组.中国缺血性脑卒中和短暂行脑缺血发作二级预防指南2010.中华神经内科杂志,2010,43(2):154
[44] Najarian R,Sullivan L,Kannela W,et al.metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke.Arch Intern Med,2006,166:106-111
[2]王新德.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29:379-381
[3] Truelsen T ,Heuschmann P ,Bonita R ,et al . Standard method for developing stroke registers in low-income and middle-in- come countries :experiences f rom a feasibility study of a step-wise approach to stroke surveillance (STEPS Stroke) [J] . Lancet Neurol, 2007 ,6 :134-139
[4] Hirano T. Latest clinical trend of stroke epidemiology shown by Stroke Data Bank[J]. Nippon Rinsho ,2006 ,28 :6447-6450
[5] Liu M ,Wu B ,Wang WZ ,et al . Stroke in China :Epidemiology prevention and management strategies[J]. Lancet Neurol,2007 ,6 :456-464
[6]安中平,张东威,巫嘉陵.2103例脑卒中登记患者发病危险因素分析[J].中华老年心脑血管病杂志,2008,(10) 4 :283-285
[7] Seenan P ,Long M ,Langhorne P. Stroke units in their natural habitat . Systematic review of observational studies[J]. Stroke,2007 ,38 :1886-1892
[8] Hozawa A ,Murakami Y,Okamura T. Relation of adult height with stroke mortality in Japan : NIPPON DATA80[J]. Stroke ,2007,38:22-26
[9] Bang OY,Park HY,Lee PH. Improved outcome after atherosclerotic stroke in male smoker . J Neurol Sci[J] ,2007 ,260 : 432
[10] Poger X,John J,M cneil,et al. Risk factors for stroke due to cerebral infarction in young adult[J].Stroke,1997,28:1913
[11]李丽娟,李巧薇,谭少华.青年缺血性卒中的危险因素、TOAST病因分型及预后分析[J].广东医学,2008,29(6):1012-1013
[12]张润兰.青年卒中临床特点和危险因素分析[J].中国误诊学杂志,2009, 9(24) :5822-5823
[13]于克文,李玉花,赵婷婷.青年、中青年脑卒中的性别差异及危险因素分析[J].中国临床神经科学,2006,14( 1):91-92
[14]丁建平宿英英.青年脑梗死病因及危险因素分析[J].中国脑血管病杂志, 2008, 5(5):202-206
[15]刘竞丽李劲频.青年缺血性脑卒中TOAST分型的临床意义[J].卒中与神经疾病,2007,14(6):341-343
[16]沙瑞娟,张宙,余天浩,等.青年人脑梗死与脑出血患者的病因、危险因素及预后: 293例对比分析[J].中国临床康复,2004,31(8):6836-6839 [17 ]王德生,徐心,李树祥,等.中青年脑梗塞患者的临床与病理[J].中华神经科杂志, 1998,31(2):98-101
[18 ] Lee TH, HsuWC, Chen CJ, et al. Etiologic study of young ischemic stroke in Taiwan[J]. Stroke,2002,33(8):1950-1955
[19] Devic B,Bradford BurkeW, (著) ,孙继洲,孙翠梅(译) .卒中遗传学和炎性机制[J].国外医学脑血管疾病分册, 2004,12(2):155-159
[20] Hillbom M, Haapaiemi H, Juvela S, et al. Recant alcohol consumption, cigarette smoking, and cerebral infarction in young adults[ J ].Stroke, 1995, 26 (1) : 40-45
[21] Cordon DL, Bendixen BH, Adams HP J r, et al. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST Investigators[ J ]. Neurology, 1993, 43 (5) : 1021-1027
[22]申小茜.青年脑梗死48例危险因素分析[ J ].中国基层医药,2004, 11 (6) : 747
[23]沙瑞娟,张宙,余天浩,等.青年人脑梗死与脑出血患者的病因、危险因素及预后: 293例对比分析[J].中国临床康复,2004,31(8):6836-6839
[24]陈善红,朱桂香,迟兆富,等.青年脑出血137例临床分析[J].中华神经医学杂志, 2005, 4 (3) : 259-261
[25] Nightingale AL , Farmer RD. Ischemic stroke in young women,a nested case-contro l study using the UK general practice research database[J ]. Stroke, 2004, 35 (7) : 1574-1578
[26]凌峰.脑血管病理论与实践.北京:人民卫生出版社,2007,31
[27]杨永宗.动脉粥样硬化性心血管病基础与临床.北京:科学出版社(第二版),2009,14
[28]杜敢琴,黄丽娜,高奇志,等.脑卒中预后的影响因素[J].中华神经医学杂志,2005,4(1):57-59
[29]徐恩,邓兵梅,梁睿,等.脑梗死患者近期预后影响因素分析[J].中国慢性病预防与控制,2004,12(2):61-63
[30] Ginberg MD,Busto R.Combating HY perthermia in acute stroke:A singnifacant clincal concern[J].Stroke,1998,29:529-534
[31] Kammergaard LP,Jorgense HS,Rungdy JA,et al.Admission body temperature predicts long-term mortality after acute stroke[J].Stroke,2002,33(7):1759-1762
[32]傅晓华,孙佳,李鸣培.体温控制治疗影响脑卒中患者的近期功能预后.中国临床康复,2005,9(25):4-5
[33]孙现广,卢奕南.急性脑卒中后就医时间与预后的关系[J].中风与神经疾病杂志,2001,8(2):100-107
[34] Msdonna P,de Stcfano V,Coppola A,et al.Hyperhomocyste inemia and other inherited prothrombotic condition in young adult with a history of ischemic stroke.Stroke, 2002, 33:51-56
[34] Eriksson J G,Forsen T,Tuomichto J,et al.Early growth,adult income,and risk of strokestroke.Stroke,2000,31:869-874
[35]朱平辉,欧阳秀革.刘春艳动态血压参数与原发性高血压患者靶器官损害的关系中国心血管病研究杂志, 2006 ,8:13
[36]吴泽兵,张颖,谢军.血压变异性与老年高血压患者腔隙性脑梗死的关系.中国临床保健杂志, 2010,3:13
[37] Najarian R,Sullivan L,Kannela W,et al.metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke.Arch Intern Med,2006,166:106-111
[1]凌锋,脑血管病理论与实践.北京:人民卫生出版社,2007,220
[2] Eham S,Ueda M ,Naruko T,et al. Elevated levels of oxidized low density lipoprotein show a positiverelationship with the severity of acute coronary syndromes [J]. Circulation,2001,103:1955-1960
[3]陈碧珊,苏丽华.他汀类药物的研究进展[J].中国药房,2005,16(7):545-546.
[4]李虹伟,彭晖.他汀类药物非调脂作用的研究进展[J].临床药物治疗杂志,2008,6(2):49-51
[5] Hofnagel O,Luechtenborg B,Eschert H,et al.Pravastatin Inhibits Expression of Lectin-like Oxidized Low-Density Lipoprotein Receptor (LOX-1) in Watanabe Heritable Hyperlipidemic hRabbits: A New Pleiotropic Effect of Statins.Arterioscler Thromb Vasc Biol,2006,26:604-610
[6] John S,Schneider M P,Delle s C,et al. Lipid-independent effect s of statin s on endothelial function and bioavailabi1ity of nitric oxide in hypercholesterolemic patients[J].Am Heart J,2005,149:473.
[7]孔德莲,沈霞.他汀类药物的非降脂作用[J].中国临床康复,2006,40(10):117-119.
[8]Premar-Oblak J,Sobestjen M,Sabovie M.Statin treatment improves cerebral more than systemic endothelial dysfunction in patien with arterial hypertension[J].Am J Hypertens,2008,21(6):674-676
[9]徐婕,龚建祖.辛伐他汀对高血压合并动脉粥样硬化患者内皮功能的影响.心脑血管病防,2009,(9)1:17-19
[10] Ahmet Yildiz,Akif Cakar,Murat Baskurt,et a1.The efects of atorvastatin therapy on endothelial function in patients with coronary artery disease[J].Cardiovascular Ultrasound,2007,30(5):51
[11] Ortego M,Bustes C,Hemandez-Presa MA,et a1.Atorvas-tatin reduces NF-kappaB activation and ehemokine expression in vascu1 ar smooth muscle cells and mononuclear cells[J].Athero-sclerosis,1999,47:253
[12] Schonbeck U,Gerdes N,Varo N,et a1.Oxidized low--density lipoprotein augments and 3-hydroxy 3methylglutaryl coenzyme A reductase inhibitors IimitCD40 and CD40L expression in human vascularcells[J].Circulation,2002,106:2888-2893
[13] Tunon J,Marti—n-Ventura J L,Blanco-Colio LM,et a1.Mechanisms of action of statins in stroke[J].Expert Opin.Ther Targets,2007,1l:273-278
[14] Notarbartolo A,Davi G,Averna M,et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in Type Iia hypercholesterolemia[J].Arterioscler Thromb Vasc Bio,1995,15:247-251
[15] Bourcier T.Libby HMGCoA reductase inhibitors reduce plasminogen activatorinhibitor-1 expression by human vascular smooth muscle and endothelia1 cells[J] .Arterioscler Thromb Vasc Biol,2000,20:556.562
[16] Knapp A C,Huang J,Starling G,et al. Inhibitors of HMGCOA reductase sensitize human smooth muscle cells to Fasligand and cytokineinduced cell death[J].Atherosclerosis,2000,152:217-227
[17] Wong B,Lumma WC,Smith AM,et al..Statins suppress THP ledl migration and secretion of matrix metalloproteinase 9 by inhibiting gerany1geranylation [J].J LeukocBiol,2001,69:959-962
[18] Blanco-Colio LM,Martin-Ventura儿,Gomez-Guerrero C,et a1.Adiponectin plasma evels are increased by atorvastatin treatment in subjects,at high cardiovascular risk. Eur J Pharmacol,2008,10:113-116
[19]董红梅,黄岚,宋耀明等.急性冠脉综合征患者血浆氧化型低密度脂蛋白、高敏C一反应蛋白与血管内皮损伤的关系[J].中国动脉硬化杂志,2006,14(3):227-229
[20] Cortellaro M,Cofrancesco E,Arbustini E,et al. Atorvastatin and thrombogenicity of the carotid Atherosclerotic plaque:the ATROCAP study.Thromb heamost,2002,88:41-47
[21] Taylor AJ,Kent SM,Flaherty PJ,et al.ARBITER:Arterial Biology for the Investigation of Treatment Effects of Reducing Cholesterol:a randomized trial comparing the effect of atorvastatin And pravastatin on carotid intima medial thickness[J].Cieculation,2002,106:2055-2060
[22] Nisscn S.Design and methedology 0f a study to evaluatethe efect of rosuvastatin on intravascular ultrasound—derived coronary atheroma burden (ASTEROID)[J].Atheroscler Suppl,2006,84(1):4-27
[23]Amarenco P,Labreuche J,Lavallee P, et al.Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J].Stroke,2004,35:2902-2909
[24] Colhoun HM , Betteridge DJ, Durrington PN, et al . P rimary prevention of cardiovascular diseae with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabete Study(CARDS): multicentre randomized place-controlled[J] .Lancet,2004,364:685-696
[25]李桂平彭娜李绪娴等.阿托伐他汀对2型糖尿病患者血管内皮功能及颈动脉粥样硬化的影响.实用医学杂志,2009,4:631-633
[26] Sacco RL,Adams R,Albers G,et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke:CO-sponsored by the COHnei1 on Cardiovascu1ar Radiology and Intervention:the American Academyof Neurology affirms the value of this guideline[J].Circulation,2006 ;113:409-449
[27] Amarenco P,Bogouss1aVsky J,Callahan A 3rd,et a1.High-dose atorvastatin after stroke or transient ischemic attack[J].N Engl J Med,2006,355:549-559
[28] Ovbiagele B,Saver JL.Itensive statin therapy after stroke or transient ischemic attack :a SPARCL success[J].Stroke,2007,38:1110-1112
[29] Antithrombotic Trialists’Collaboration.Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324:71- 86
[30] Rashid P,Lenoardi-Bee J,Bath P.Blood pressure reduction and secondary prevention of stroke and other vascular events:a systematic review[J].Stroke,2003.34:2741-2748
[31] National Cholesterol Education Program(NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood ChoLesterol in Adults Treatment PanelⅢ.Third Report of the National Cholosterol Education Program(NCEP)Expert Panel on Detection,Evaluation.and Treatment of High Blood Cholesterol in Adults Tteatment Panel m)final report[J]. Circulation,2002,106:3143-3421
[32] Newman CB,Palmer G,Silbershatz,et a1.Safety of atorvastatin derived from analysis of 44 completed trial s in 9416 patients[J].Am J Cardiol,2003,92:670-676
[33] Davidsonn MH,Toth PP.Combination therapy in the management of cornplex dyslipidemias[J].Gurr opin Lipidol,2004,15(4):423-431
[34] de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trial[J].JAMA,2004, 292:1307-1316.
[35] O’Regan C,Wu P,Arora P,et a1.Statin therapy in stroke prevention:a meta—analysis involving l2l,000 patients[J].Am J Med 2008,121:24-33.
[36] Alsheikh-Ali AA,M addukuri PV,Han H,et a1.Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes,Rhabdomyolysis,and Cancer[J].J Am Coil Cardiol,2007,50:409-418
[37]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35:390-427.
[38]张伟杰,唐伟方.他汀类药物的药动学及与其他药物的相互作用[J].药学进展,2009,33(3)119-123
[39] Sever PS,D ahlof B,Poulter NR,et a1.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than-average cholesterol concertrations:a multicentre randomized controlled trial[J].Lancet,2003,361:1149-1158.
[40] Schwartz G G, Olsson A G,Ezekowitz M D, et a1.Efects of atorvas tain on early recurrent ischemic events in acute coronary syndormes:the MIRACLE study.A randomizedcontrolled trial[J].JAMA,2001,285(1711):1718-1725.
[41] Adams RJ,Albers G,Alberts MJ,et a1.Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack[J]. Stroke,2008,39:1647-1652.
[42]他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组.他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识(更新版).中华内科杂志,2008,47(10):873-875
[43]中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组.中国缺血性脑卒中和短暂行脑缺血发作二级预防指南2010.中华神经内科杂志,2010,43(2):154
[44] Najarian R,Sullivan L,Kannela W,et al.metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke.Arch Intern Med,2006,166:106-111